Forum Discussion

cactusk's avatar
cactusk
Member
2 months ago

Giredestrant - SERD

Hello there, 

Reading the news coming out of the San Ontonio Breast Cancer Symposium this year (happening right now) and there is a very positive, yet early, study on a new SERD on Early stage BC in the Lidera trial. Does anyone know about this or is part of the trial? It seems that there was recruitment in Victoria? Keen to hear. 

hormone-therapy
side-effects

1 Reply

  • arpie's avatar
    arpie
    Member
    2 months ago

    I hadn't heard of that one ...... and yours was the first mention of it on here!

    Some info here from Trials CancerVic - looks like it has been 'closed to new participants' for a while, tho it is still 'active'.
    https://trials.cancervic.org.au/details.aspx?ID=feed-cta-trial239

    AI says this:

    The lidERA trial (also known as the lidERA Breast Cancer study) was a global Phase III clinical trial that included participation from multiple cancer centers in Australia. The study evaluated the efficacy and safety of a new oral drug called giredestrant in treating early-stage breast cancer. 

    Key Information about the lidERA Trial

    • Purpose: The primary goal of the trial was to determine if giredestrant, an oral selective estrogen receptor degrader (SERD), could reduce the risk of breast cancer recurrence more effectively than standard-of-care hormone therapies (such as tamoxifen or aromatase inhibitors) after surgery.
    • Participants: The trial enrolled over 4,100 people globally with estrogen receptor-positive (ER+), HER2-negative early breast cancer who were considered at medium or high risk of recurrence.
    • Treatment: Participants were randomly assigned to receive either 30mg of giredestrant daily or a physician's choice of standard oral hormone therapy for a period of up to five years, or until the cancer returned or side effects became unacceptable.
    • Status & Results: The trial has concluded its primary analysis, and recent results (as of December 2025) indicate that giredestrant reduced the risk of invasive disease recurrence or death by 30% compared to standard therapy. These positive results suggest giredestrant could become a new standard in endocrine therapy. 

    Australian Involvement

    Australian cancer centers were part of the international study, including the Border Medical Oncology Research Unit and others across Victoria and South Australia. 

    For those interested in current or future clinical trials in Australia, you can find information through official resources like the Australian Clinical Trials website or the Victorian Cancer Trials Link.